publication date: Mar. 30, 2017
CCL March 2017 - Mar. 30, 2017

March 2017 PDF

  Multiple Myeloma Carfilzomib produces OS benefit vs. bortezomib in relapsed, refractory disease

Amgen announced positive results from a planned overall survival interim analysis of the Phase III head-to-head ENDEAVOR trial.

  Chronic Myeloid Leukemia NEJM publishes long-term results of Gleevec for 1,106 patients worldwide

The New England Journal of Medicine published results from a nearly 11-year follow-up study, that showed an estimated overall survival rate of 83.3 percent.

  Breast Cancer Phase III MONARCH 2 study of abemaciclib meets primary endpoint of PFS

Eli Lilly and Co. said its MONARCH 2 trial of abemaciclib met the primary endpoint of progression-free survival. The phase III study evaluated abemaciclib, a cyclin-dependent kinase  4 and CDK 6 inhibitor, in combination with fulvestrant in women with hormone-receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer who have relapsed or progressed after endocrine therapy.

Perjeta plus Herceptin produce significant improvement in invasive disease-free survival in HER2-positive early breast cancer vs. Herceptin and chemo alone Sacituzumab govitecan produces early, … Continue reading CCL March 2017

To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2017 The Cancer Letter Inc.